CB6F1-2*hHRAS Mouse
Product Name
CB6F1-2*hHRAS Mouse
Product ID
C001643
Strain Name
BALB/c;B6JCya-Gt(ROSA)26Sorem1(hHRAS*c.450+180A>G)Igs2em1(hHRAS*c.450+180A>G)/Cya
Backgroud
BALB/c;B6JCya
Status
When using this mouse strain in a publication, please cite “CB6F1-2*hHRAS Mouse (Catalog C001643) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
Gene Alias
CTLO, HAMSV, HRAS1, RASH1, p21ras, C-H-RAS, H-RASIDX, C-BAS/HAS, C-HA-RAS1
NCBI ID
Chromosome
Chr 11
MGI ID
--
Datasheet
Strain Description
The HRas oncogene (HRAS), also known as the Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS), is a member of the Ras oncogene family, which also includes KRAS and NRAS. All members of this family are associated with the development of mammalian sarcoma retroviruses [1]. HRAS encodes the H-Ras protein, a small GTPase responsible for transmitting signals from cell surface receptors to the nucleus, regulating cell proliferation, survival, and differentiation. HRAS is primarily expressed in various tissues, including the brain, heart, and skeletal muscle, and is involved in controlling the cellular response to growth factors. As a member of the small GTPase family, HRAS acts as a molecular switch, cycling between active and inactive states to influence key cellular processes. Mutations in the HRAS gene can lead to abnormal signal transduction, commonly found in tumors of stratified epithelial tissues, such as bladder cancer, thyroid cancer, and head and neck squamous cell carcinoma. Additionally, HRAS is associated with Costello syndrome, a genetic disorder characterized by developmental delays and an increased risk of tumors [2-3].
Early studies have shown that genotoxic carcinogens shorten the latency period and increase the incidence of malignant tumors in rasH2 mice, which carry the human HRAS (c-Ha-ras) oncogene, compared to non-transgenic mice. Therefore, rasH2 mice are ideal animal models for rapid carcinogenicity testing [4-5]. Further research has shown that F1 hybrid mice (CB6F1 background rasH2 mice) obtained by mating male C57BL/6J mice carrying the human prototype c-Ha-ras gene with female BALB/c mice are significantly more sensitive to both mutagenic and non-mutagenic carcinogens than control mice [5]. These mice are highly sensitive to the carcinogenicity of both genotoxic and non-genotoxic compounds while showing no response to non-carcinogens [6]. Between 12 to 18 months of age, rasH2 mice primarily develop spontaneous alveolar adenomas/bronchial adenomas/adenocarcinomas, splenic hemangiomas/hemangiosarcomas, and a smaller number of skin and gastric papillomas and lymphomas [4]. In the 1990s, this mouse model was officially approved by the FDA for carcinogenicity evaluations in drug safety assessments, reducing the standard two-year carcinogenicity test in common rodents to six months.
The CB6F1-2*hHRAS mouse was obtained by mating double-genotype B6-Rosa26-hHRAS[KI/+]; H11-hHRAS[KI/+] mice with BALB/cAnCya mice. The double-genotype B6-Rosa26-hHRAS[KI/+]; H11-hHRAS[KI/+] mice were generated by crossing Rosa26-hHRAS mice (Catalog No.: I001213) with H11-hHRAS mice, both on the C57BL/6JCya background. This model carries two copies of the human proto-oncogene c-Ha-ras on a C57BL/6J × BALB/c hybrid background (i.e., CB6F1 background) and exhibits increased sensitivity to both genotoxic and non-genotoxic human carcinogens. CB6F1-2*hHRAS mice can be used for rapid in vivo testing of the carcinogenicity of genotoxic and non-genotoxic compounds, studying the impact of HRAS oncogene point mutations on tumorigenesis and development, and developing tumor prevention or suppression therapies.
Reference
Parikh C, Subrahmanyam R, Ren R. Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice. Cancer Res. 2007 Aug 1;67(15):7139-46.
Untch BR, Dos Anjos V, Garcia-Rendueles MER, Knauf JA, Krishnamoorthy GP, Saqcena M, Bhanot UK, Socci ND, Ho AL, Ghossein R, Fagin JA. Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers. Cancer Res. 2018 Aug 15;78(16):4642-4657.
Wu XY, Liu WT, Wu ZF, Chen C, Liu JY, Wu GN, Yao XQ, Liu FK, Li G. Identification of HRAS as cancer-promoting gene in gastric carcinoma cell aggressiveness. Am J Cancer Res. 2016 Sep 1;6(9):1935-1948.
Maronpot RR, Mitsumori K, Mann P, Takaoka M, Yamamoto S, Usui T, Okamiya H, Nishikawa S, Nomura T. Interlaboratory comparison of the CB6F1-Tg rasH2 rapid carcinogenicity testing model. Toxicology. 2000 May 5;146(2-3):149-59.
Yamamoto S, Urano K, Nomura T. Validation of transgenic mice harboring the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Toxicol Lett. 1998 Dec 28;102-103:473-8.
Sehata S, Maejima T, Watanabe M, Ogata S, Makino T, Tanaka K, Manabe S, Takaoka M. Twenty-six-Week carcinogenicity study of chloroform in CB6F1 rasH2-transgenic mice. Toxicol Pathol. 2002 May-Jun;30(3):328-38.
Strain Strategy
Figure2. Gene editing strategy of Rosa26-hHRAS mice. The c.450+180A>G point mutation was introduced into intron 4 Human HRAS, and the “Mutant human HRAS genome” cassette was cloned into intron 1 of ROSA26 in reverse orientation.
Figure2. Gene editing strategy of H11-hHRAS mice. The c.450+180A>G point mutation was introduced into intron 4 Human HRAS, and the “Mutant human HRAS genome” cassette was inserted into H11 locus.
Application Area
Rapid in vivo test for carcinogenicity of genotoxic and non-genotoxic compounds;
Impact of HRAS oncogene point mutations on tumorigenesis and development.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.